September 25, 2018 10:19 AM EDTUpdated 11:34 AM
News Briefing

Take­da high­lights promis­ing front­line re­sults for ALK+ NSCLC drug Alun­brig; TGTX shares plunge on PhI­II sna­fu

John Carroll

Editor & Founder

→ Take­da un­veiled pos­i­tive PFS da­ta for its ALK+ NSCLC drug Alun­brig (briga­tinib) to­day, un­der­scor­ing a haz­ard ra­tio of 0.49 — a 51% drop in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

A service from the Financial Times